Sfoglia per Corso Farmacologia e tossicologia
A NAM-based approach for addressing key knowledge gaps in the assessment of potential hazards associated to nanocellulose oral exposure
2025
Neurodegenerative and neuroinflammatory mechanisms in neurological and psychiatric disorders
2026
New strategies leveraging ALIAmides in acute and chronic anti-inflammatory therapies
2025
Novel promising pharmacological targets and drugs for the treatment of neuropathic pain: focusing on prokineticin system and selective A3 adenosine receptor (A3AR) agonists in an animal model
2019
A novel selective cell-permeable peptide disrupts presynaptic JNK2-STX1a interaction, providing neuroprotection and preventing glutamate-mediated excitotoxicity
2018
Oleoylethanolamide in the gut-brain axis
2019
Oleoylethanolamide in the homeostatic and non-homeostatic control of eating
2019
Pain and analgesic use associated with sres in patients with advanced breast cancer and bone metastases treated with bone-modifying agents: a retrospective observational study
2024
Peroxidation of leukocytes index ratio and a functional mathematical index: their potential application in screening of non-communicable diseases
2018
Pesticides exposure and premature thelarche: experimental and epidemiological tools for toxicological assessment
2022
Pharmacological characterization of new compounds and herbal derivatives for pain and inflammation treatment
2022
Pharmacological modulation of lipid metabolism as a regulator of cellular plasticity, homeostasis, and stress responses in colon and liver cell models
2026
Pharmacological modulation of paracannabinoid tone in peripheral and central alterations associated with maladaptive eating behaviors
2026
Pharmacological modulation of the gut microbiota and epithelial barrier: new therapeutic perspectives in obesity
2026
Pre-clinical evaluation of novel pharmacological targets for the treatment of obesity and eating disorders: focus on Oleoylethanolamide and the oxytocinergic system
2024
Preclinical pharmacological characterization of GLP-1 agonists, PPARα activators, and peripheral CB1 antagonists in the treatment of high-fat high-fructose diet–induced metabolic and neuroendocrine dysregulation
2026
Prospects for new drugs to treat aberrant eating patterns: possible role of Oleoylethanolamide
2022
Real-world clinical outcomes in HER2 positive and negative metastatic breast cancer patients treated with Abemaciclib, Ribociclib and Trastuzumab deruxtecan
2025
Resilience and susceptibility to stress-related disorders: insights from animal models
2021
Retrospective and observational protocol on the reduction of the time needed for the evaluation of drug interactions and real world evidence in the treatment of Melanoma and Non Small Cell Lung Cancer
2025
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile